



GI Dynamics, Inc. – ASX Announcement

## **2015 Annual Meeting of Stockholders Access for Participants by Webcast and Conference Call**

**LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 27 May 2015** – GI Dynamics, Inc. (ASX: **GID**) (**GI Dynamics** or the **Company**) will hold its 2015 Annual Meeting of Stockholders on Tuesday, June 9, 2015 at 9:00 a.m. Australian Eastern Standard Time (which is 7:00 p.m. on Monday, June 8, 2015 U.S. Eastern Daylight Time) at the offices of DLA Piper Australia, Level 22, No.1 Martin Place, Sydney, NSW, 2000, Australia.

If not attending in person, the meeting can be accessed through conference call and webcast.

### **Accessing the Annual Meeting of Stockholders via Webcast:**

A live webcast of the call will be available on the GI Dynamics website at [investor.gidynamics.com](http://investor.gidynamics.com). The webcast can be directly accessed at: <http://edge.media-server.com/m/p/csaea5ow/lan/en>.

### **Accessing the Annual Meeting of Stockholders via Telephone:**

For those preferring to listen by telephone, please dial in five minutes prior to the start of the call and provide the **passcode 39467021**. Regional dial-in numbers are as follows:

- **United States** callers please dial toll-free **1 (888) 771-4371**
- **Australian** callers please dial toll-free **1 800 507 265**
- **Other International** callers please dial **1 (847) 585-4405**

**Robert Solomon**  
**Vice President, Finance & Company Secretary**

### **About GI Dynamics**

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier<sup>®</sup>, the first endoscopically-delivered device therapy approved for the treatment of obese type 2 diabetes with BMI  $\geq 30$  kg/m<sup>2</sup>, or obese patients with BMI  $\geq 30$  kg/m<sup>2</sup> with  $\geq 1$  comorbidities, or obese patients with BMI  $>35$  kg/m<sup>2</sup>. The liner is indicated for a maximum implant duration of 12 months. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit [www.gidynamics.com](http://www.gidynamics.com).

[www.gidynamics.com](http://www.gidynamics.com)

US OFFICE & HEADQUARTERS:  
EUROPEAN OFFICE:  
AUSTRALIAN OFFICE:

25 Hartwell Avenue, Lexington MA 02421 T +1 (781) 357-3300 F +1 (781) 357-3301  
Prinzenallee 7, 40549 Dusseldorf, Germany T: +49 211 5239 1572  
Level 8, 17-19 Bridge Street, Sydney, NSW 2000 T +61 2 9325 9046

GI Dynamics, Inc., is a corporation incorporated in Delaware, USA, whose stockholders have limited liability. ARBN 151 239 388

**Forward-Looking Statements**

This announcement contains forward-looking statements concerning: our development and commercialization plans; our potential revenues and revenue growth, costs, excess inventory, profitability and financial performance; our ability to obtain reimbursement for our products; our clinical trials, and associated regulatory submissions and approvals; the number and location of commercial centres offering the EndoBarrier<sup>®</sup>; and our intellectual property position. These forward-looking statements are based on the current estimates and expectations of future events by the management of GI Dynamics, Inc. as of the date of this announcement and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the possibility that clinical trials will not be successful or confirm earlier results; risks associated with obtaining funding from third parties; risks relating to the timing and costs of clinical trials, the timing of regulatory submissions, the timing, receipt and maintenance of regulatory approvals, the timing and amount of other expenses, and the timing and extent of third-party reimbursement; risks associated with commercial product sales, including product performance; competition; risks related to market acceptance of products; intellectual property risks; risks related to excess inventory; risks related to assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches, future financial results and other factors including those described in our filings with the U.S. Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

**Investor Enquiries:**

United States  
Michael Dale, President & CEO  
+1 (781) 357-3310

Australia  
David Allen or John Granger  
Hawkesbury Partners Pty Limited  
+61 2 9325 9046

**Media Enquiries:**

United States/Europe:  
Bill Berry, Berry & Company Public Relations, LLC  
+1 (212) 253-8881

[www.gidynamics.com](http://www.gidynamics.com)

US OFFICE & HEADQUARTERS: 25 Hartwell Avenue, Lexington MA 02421 T +1 (781) 357-3300 F +1 (781) 357-3301  
EUROPEAN OFFICE: Prinzenallee 7, 40549 Dusseldorf, Germany T: +49 211 5239 1572  
AUSTRALIAN OFFICE: Level 8, 17-19 Bridge Street, Sydney, NSW 2000 T +61 2 9325 9046  
GI Dynamics, Inc., is a corporation incorporated in Delaware, USA, whose stockholders have limited liability. ARBN 151 239 388